Update regarding opportunities for orthopaedic surgeons to contribute to postmarket surveillance of potential safety issues for orthopaedic medical devices marketed in the United States.
作者信息
Devlin Vincent J
机构信息
Division of Orthopedic Devices, Center for Devices and Radiological Health, Office of Device Evaluation, U.S. Food and Drug Administration, Silver Spring, MD, USA.
出版信息
Arthroplast Today. 2017 Oct 16;3(4):205-206. doi: 10.1016/j.artd.2017.09.003. eCollection 2017 Dec.
Abstract
摘要
相似文献
1
Update regarding opportunities for orthopaedic surgeons to contribute to postmarket surveillance of potential safety issues for orthopaedic medical devices marketed in the United States.
Arthroplast Today. 2017 Oct 16;3(4):205-206. doi: 10.1016/j.artd.2017.09.003. eCollection 2017 Dec.
2
How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Clin Orthop Relat Res. 2016 Apr;474(4):1053-68. doi: 10.1007/s11999-015-4634-x. Epub 2015 Nov 19.
3
Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
JAMA. 2015 Aug 11;314(6):604-12. doi: 10.1001/jama.2015.8761.
4
Analysis of FDA-Approved Orthopaedic Devices and Their Recalls.
J Bone Joint Surg Am. 2016 Mar 16;98(6):517-24. doi: 10.2106/JBJS.15.00286.
5
Device Safety.
Otolaryngol Clin North Am. 2019 Feb;52(1):103-114. doi: 10.1016/j.otc.2018.08.013. Epub 2018 Sep 20.
6
[United States Medical Device Postmarket Surveillance System Operational Experience and Learning].
Zhongguo Yi Liao Qi Xie Za Zhi. 2017 Mar 30;41(2):123-126. doi: 10.3969/j.issn.1671-7104.2017.02.013.
7
The FDA process for the evaluation and approval of orthopaedic devices.
J Am Acad Orthop Surg. 2008 May;16(5):260-7. doi: 10.5435/00124635-200805000-00004.
8
Oversight overhaul: eliminating the premarket review of medical devices and implementing a provider-centered postmarket surveillance strategy.
Food Drug Law J. 2011;66(3):377-404, ii.
10
Technology assessment of medical devices at the Center for Devices and Radiological Health.
Am J Manag Care. 1998 Sep 25;4 Spec No:SP129-35.
本文引用的文献
1
An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials.
N Engl J Med. 2017 Apr 6;376(14):1350-1357. doi: 10.1056/NEJMra1512592.
2
Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.
JAMA. 2017 Feb 21;317(7):693-694. doi: 10.1001/jama.2017.0410.
3
Need for a National Evaluation System for Health Technology.
JAMA. 2016 Sep 20;316(11):1153-4. doi: 10.1001/jama.2016.8708.
4
Reporting and notification of adverse events in orthopaedics.
J Am Acad Orthop Surg. 2010 Apr;18(4):193-8. doi: 10.5435/00124635-201004000-00002.
5
FDA medical device approval: things you didn't learn in medical school or residency.
Am J Orthop (Belle Mead NJ). 2007 Aug;36(8):407-12.
6
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
JAMA. 1993 Jun 2;269(21):2765-8. doi: 10.1001/jama.269.21.2765.
Zotero 插件